Print

Sankyo Pharma GmbH Simplifying Clinical Trial Communications With IntraLinks, Inc.; Pharma Leader To Manage Document Flow For ROADMAP Trial In More Than 22 European Countries 
10/19/2005 5:09:53 PM

IntraLinks, the leading pharmaceutical industry provider of secure document exchange technology, announced today that Sankyo Pharma GmbH will use its secure online workspaces to manage document flow for its ROADMAP (Randomised Olmesartan And Diabetes MicroAlbuminuria Prevention) clinical trial. This study will involve 22 countries and about 220 centres throughout Western and Eastern Europe, and will recruit more than 4,400 patients. ROADMAP is the first ever large-scale multinational trial to study whether the compound Olmesartan, the latest Angiotensin II Receptor Blocker (ARB), can prevent the onset of microalbuminuria -- an early sign of kidney disease -- in patients with type 2 diabetes.
//-->